Pharos Capital Launches Verdi Oncology through Horizon Oncology Acquisition

We represented Pharos Capital Group in its acquisition of Horizon Oncology. The acquisition marks the launch of Verdi Oncology, Inc., an oncology practice and clinical research management company. Financial terms of the transaction were not publicly disclosed.

Horizon Oncology offers a wide range of comprehensive cancer services to patients, including advanced technological options, premier clinical expertise and cutting edge clinical trials opportunities, with a focus on early phase trials.

Pharos Capital Group is an SEC Registered Investment Advisor. As of March 2018, Pharos has invested in 51 companies and currently has over $690 million of private equity assets under management.

You Also May Be Interested In:

  • Representation of Family Legacy, LLC and Harpeth Hills Memory Gardens, Inc. in their sale to Park Lawn Corporation (TSX: PLC), a company that provides goods and services associated with the disposition and memorialization of human remains

    We represented Family Legacy, LLC and Harpeth Hills Memory Gardens, Inc. in their sale to Park Lawn Corporation (TSX: PLC),...
    Client Type: Private Company
  • Representation of WellCare Health Plans, Inc., a government-focused managed care provider, in its merger with Centene Corporation (NYSE: CNC) for $17.3 billion

    We represented WellCare Health Plans, Inc. in its merger with Centene Corporation (NYSE: CNC) for $17.3 billion. The combined company...
    Client Type: Public Company
  • Representation of LFM Capital in its sale of EDSCO Fasteners, a leading supplier of foundation anchoring systems for critical infrastructure installations, to MiddleGround Capital

    We represented LFM Capital in its sale of EDSCO Fasteners, a leading supplier of foundation anchoring systems for critical infrastructure...
    Client Type: Private Company